Skip to main content
Erschienen in: Osteoporosis International 11/2008

01.11.2008 | Review

Sex hormones, their receptors and bone health

verfasst von: K. Venken, F. Callewaert, S. Boonen, D. Vanderschueren

Erschienen in: Osteoporosis International | Ausgabe 11/2008

Einloggen, um Zugang zu erhalten

Abstract

Sex steroids regulate skeletal maturation and preservation in both men and women, as already recognized in the 1940s by Albright and Reifenstein. The impact of gonadal insufficiency on skeletal integrity has been widely recognized in adult men and women ever since. In the context of their skeletal actions, androgens and estrogens are no longer considered as just male and female hormones, respectively. Androgens can be converted into estrogens within the gonads and peripheral tissues and both are present in men and women, albeit in different concentrations. In the late 1980s, sex steroid receptors were discovered in bone cells. However, the understanding of sex steroid receptor activation and translation into biological skeletal actions is still incomplete. Due to the complex metabolism, sex steroids may have not only endocrine but also paracrine and/or autocrine actions. Also, circulating sex steroid concentrations do not necessarily reflect their biological activity due to strong binding to sex hormone binding globulin (SHBG). Finally, sex steroid signaling may include genomic and non-genomic effects in bone and non-bone cells. This review will focus on our current understanding of gonadal steroid metabolism, receptor activation, and their most relevant cellular and biological actions on bone.
Literatur
1.
Zurück zum Zitat Melton LJ 3rd, Kan SH, Wahner HW, Riggs BL (1988) Lifetime fracture risk: an approach to hip fracture risk assessment based on bone mineral density and age. J Clin Epidemiol 41:985–994CrossRefPubMed Melton LJ 3rd, Kan SH, Wahner HW, Riggs BL (1988) Lifetime fracture risk: an approach to hip fracture risk assessment based on bone mineral density and age. J Clin Epidemiol 41:985–994CrossRefPubMed
2.
Zurück zum Zitat Wilson JD (2001) The role of 5alpha-reduction in steroid hormone physiology. Reprod Fertil Dev 13:673–678CrossRefPubMed Wilson JD (2001) The role of 5alpha-reduction in steroid hormone physiology. Reprod Fertil Dev 13:673–678CrossRefPubMed
3.
Zurück zum Zitat Simpson ER, Clyne C, Rubin G, Boon WC, Robertson K, Britt K, Speed C, Jones M (2002) Aromatase–a brief overview. Annu Rev Physiol 64:93–127CrossRefPubMed Simpson ER, Clyne C, Rubin G, Boon WC, Robertson K, Britt K, Speed C, Jones M (2002) Aromatase–a brief overview. Annu Rev Physiol 64:93–127CrossRefPubMed
4.
Zurück zum Zitat Kaufman JM, Vermeulen A (2005) The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev 26:833–876CrossRefPubMed Kaufman JM, Vermeulen A (2005) The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev 26:833–876CrossRefPubMed
5.
Zurück zum Zitat Vermeulen A, Verdonk L (1968) Studies on the binding of testosterone to human plasma. Steroids 11:609–635CrossRefPubMed Vermeulen A, Verdonk L (1968) Studies on the binding of testosterone to human plasma. Steroids 11:609–635CrossRefPubMed
6.
Zurück zum Zitat Giorgi EP, Stein WD (1981) The transport of steroids into animal cells in culture. Endocrinology 108:688–697CrossRefPubMed Giorgi EP, Stein WD (1981) The transport of steroids into animal cells in culture. Endocrinology 108:688–697CrossRefPubMed
7.
Zurück zum Zitat Khosla S, Melton LJ, Atkinson EJ, O-Fallon WM, Klee GG, Riggs BL (1998) Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men: a key role for bio-available estrogen. J Clin Endocrinol Metab 83:2266–2275PubMed Khosla S, Melton LJ, Atkinson EJ, O-Fallon WM, Klee GG, Riggs BL (1998) Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men: a key role for bio-available estrogen. J Clin Endocrinol Metab 83:2266–2275PubMed
8.
Zurück zum Zitat Vanderschueren D, Vandenput L, Boonen S, Lindberg MK, Bouillon R, Ohlsson C (2004) Androgens and bone. Endocr Rev 25:389–425CrossRefPubMed Vanderschueren D, Vandenput L, Boonen S, Lindberg MK, Bouillon R, Ohlsson C (2004) Androgens and bone. Endocr Rev 25:389–425CrossRefPubMed
9.
Zurück zum Zitat Tsai MJ, O’Malley BW (1994) Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem 63:451–486CrossRefPubMed Tsai MJ, O’Malley BW (1994) Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem 63:451–486CrossRefPubMed
10.
Zurück zum Zitat McKenna NJ, Lanz RB, O’Malley BW (1999) Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev 20:321–344PubMed McKenna NJ, Lanz RB, O’Malley BW (1999) Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev 20:321–344PubMed
11.
Zurück zum Zitat Shang Y, Myers M, Brown M (2002) Formation of the androgen receptor transcription complex. Mol Cell 9:601–610CrossRefPubMed Shang Y, Myers M, Brown M (2002) Formation of the androgen receptor transcription complex. Mol Cell 9:601–610CrossRefPubMed
12.
Zurück zum Zitat Weigel NL, Zhang Y (1998) Ligand-independent activation of steroid hormone receptors. J Mol Med 76:469–479CrossRefPubMed Weigel NL, Zhang Y (1998) Ligand-independent activation of steroid hormone receptors. J Mol Med 76:469–479CrossRefPubMed
13.
Zurück zum Zitat Kushner PJ, Agard DA, Greene GL, Scanlan TS, Shiau AK, Uht RM, Webb P (2000) Estrogen receptor pathways to AP-1. J Steroid Biochem Mol Biol 74:311–317CrossRefPubMed Kushner PJ, Agard DA, Greene GL, Scanlan TS, Shiau AK, Uht RM, Webb P (2000) Estrogen receptor pathways to AP-1. J Steroid Biochem Mol Biol 74:311–317CrossRefPubMed
14.
Zurück zum Zitat Whitmarsh AJ, Davis RJ (1996) Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways. J Mol Med 74:589–607CrossRefPubMed Whitmarsh AJ, Davis RJ (1996) Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways. J Mol Med 74:589–607CrossRefPubMed
15.
Zurück zum Zitat Wiren KM, Toombs AR, Zhang XW (2004) Androgen inhibition of MAP kinase pathway and Elk-1 activation in proliferating osteoblasts. J Mol Endocrinol 32:209–226CrossRefPubMed Wiren KM, Toombs AR, Zhang XW (2004) Androgen inhibition of MAP kinase pathway and Elk-1 activation in proliferating osteoblasts. J Mol Endocrinol 32:209–226CrossRefPubMed
16.
Zurück zum Zitat Safe S (2001) Transcriptional activation of genes by 17 beta-estradiol through estrogen receptor-Sp1 interactions. Vitam Horm 62:231–252CrossRefPubMed Safe S (2001) Transcriptional activation of genes by 17 beta-estradiol through estrogen receptor-Sp1 interactions. Vitam Horm 62:231–252CrossRefPubMed
17.
Zurück zum Zitat Falkenstein E, Tillmann HC, Christ M, Feuring M, Wehling M (2000) Multiple actions of steroid hormones–a focus on rapid, nongenomic effects. Pharmacol Rev 52:513–556PubMed Falkenstein E, Tillmann HC, Christ M, Feuring M, Wehling M (2000) Multiple actions of steroid hormones–a focus on rapid, nongenomic effects. Pharmacol Rev 52:513–556PubMed
18.
Zurück zum Zitat Losel RM, Falkenstein E, Feuring M, Schultz A, Tillmann HC, Rossol-Haseroth K, Wehling M (2003) Nongenomic steroid action: controversies, questions, and answers. Physiol Rev 83:965–1016CrossRefPubMed Losel RM, Falkenstein E, Feuring M, Schultz A, Tillmann HC, Rossol-Haseroth K, Wehling M (2003) Nongenomic steroid action: controversies, questions, and answers. Physiol Rev 83:965–1016CrossRefPubMed
19.
Zurück zum Zitat Pietras RJ, Szego CM (1977) Specific binding sites for oestrogen at the outer surfaces of isolated endometrial cells. Nature 265:69–72CrossRefPubMed Pietras RJ, Szego CM (1977) Specific binding sites for oestrogen at the outer surfaces of isolated endometrial cells. Nature 265:69–72CrossRefPubMed
20.
Zurück zum Zitat Konoplya EF, Popoff EH (1992) Identification of the classical androgen receptor in male rat liver and prostate cell plasma membranes. Int J Biochem 24:1979–1983CrossRefPubMed Konoplya EF, Popoff EH (1992) Identification of the classical androgen receptor in male rat liver and prostate cell plasma membranes. Int J Biochem 24:1979–1983CrossRefPubMed
21.
Zurück zum Zitat Song RX, McPherson RA, Adam L, Bao Y, Shupnik M, Kumar R, Santen RJ (2002) Linkage of rapid estrogen action to MAPK activation by ERalpha-Shc association and Shc pathway activation. Mol Endocrinol 16:116–127PubMed Song RX, McPherson RA, Adam L, Bao Y, Shupnik M, Kumar R, Santen RJ (2002) Linkage of rapid estrogen action to MAPK activation by ERalpha-Shc association and Shc pathway activation. Mol Endocrinol 16:116–127PubMed
22.
Zurück zum Zitat Migliaccio A, Castoria G, Di Domenico M, de Falco A, Bilancio A, Lombardi M, Barone MV, Ametrano D, Zannini MS, Abbondanza C, Auricchio F (2000) Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation. Embo J 19:5406–5417CrossRefPubMedPubMedCentral Migliaccio A, Castoria G, Di Domenico M, de Falco A, Bilancio A, Lombardi M, Barone MV, Ametrano D, Zannini MS, Abbondanza C, Auricchio F (2000) Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation. Embo J 19:5406–5417CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Kousteni S, Bellido T, Plotkin LI, O’Brien CA, Bodenner DL, Han L, Han K, DiGregorio GB, Katzenellenbogen JA, Katzenellenbogen BS, Roberson PK, Weinstein RS, Jilka RL, Manolagas SC (2001) Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell 104:719–730PubMed Kousteni S, Bellido T, Plotkin LI, O’Brien CA, Bodenner DL, Han L, Han K, DiGregorio GB, Katzenellenbogen JA, Katzenellenbogen BS, Roberson PK, Weinstein RS, Jilka RL, Manolagas SC (2001) Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell 104:719–730PubMed
24.
Zurück zum Zitat Kousteni S, Han L, Chen JR, Almeida M, Plotkin LI, Bellido T, Manolagas SC (2003) Kinase-mediated regulation of common transcription factors accounts for the bone-protective effects of sex steroids. J Clin Invest 111:1651–1664CrossRefPubMedPubMedCentral Kousteni S, Han L, Chen JR, Almeida M, Plotkin LI, Bellido T, Manolagas SC (2003) Kinase-mediated regulation of common transcription factors accounts for the bone-protective effects of sex steroids. J Clin Invest 111:1651–1664CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Kousteni S, Chen JR, Bellido T, Han L, Ali AA, O’Brien CA, Plotkin L, Fu Q, Mancino AT, Wen Y, Vertino AM, Powers CC, Stewart SA, Ebert R, Parfitt AM, Weinstein RS, Jilka RL, Manolagas SC (2002) Reversal of bone loss in mice by nongenotropic signaling of sex steroids. Science 298:843–846CrossRefPubMed Kousteni S, Chen JR, Bellido T, Han L, Ali AA, O’Brien CA, Plotkin L, Fu Q, Mancino AT, Wen Y, Vertino AM, Powers CC, Stewart SA, Ebert R, Parfitt AM, Weinstein RS, Jilka RL, Manolagas SC (2002) Reversal of bone loss in mice by nongenotropic signaling of sex steroids. Science 298:843–846CrossRefPubMed
26.
Zurück zum Zitat Moverare S, Dahllund J, Andersson N, Islander U, Carlsten H, Gustafsson JA, Nilsson S, Ohlsson C (2003) Estren is a selective estrogen receptor modulator with transcriptional activity. Mol Pharmacol 64:1428–1433CrossRefPubMed Moverare S, Dahllund J, Andersson N, Islander U, Carlsten H, Gustafsson JA, Nilsson S, Ohlsson C (2003) Estren is a selective estrogen receptor modulator with transcriptional activity. Mol Pharmacol 64:1428–1433CrossRefPubMed
27.
Zurück zum Zitat Windahl SH, Galien R, Chiusaroli R, Clement-Lacroix P, Morvan F, Lepescheux L, Nique F, Horne WC, Resche-Rigon M, Baron R (2006) Bone protection by estrens occurs through non-tissue-selective activation of the androgen receptor. J Clin Invest 116:2500–2509CrossRefPubMedPubMedCentral Windahl SH, Galien R, Chiusaroli R, Clement-Lacroix P, Morvan F, Lepescheux L, Nique F, Horne WC, Resche-Rigon M, Baron R (2006) Bone protection by estrens occurs through non-tissue-selective activation of the androgen receptor. J Clin Invest 116:2500–2509CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Centrella M, McCarthy TL, Chang WZ, Labaree DC, Hochberg RB (2004) Estren (4-estren-3alpha,17beta-diol) is a prohormone that regulates both androgenic and estrogenic transcriptional effects through the androgen receptor. Mol Endocrinol 18:1120–1130CrossRefPubMed Centrella M, McCarthy TL, Chang WZ, Labaree DC, Hochberg RB (2004) Estren (4-estren-3alpha,17beta-diol) is a prohormone that regulates both androgenic and estrogenic transcriptional effects through the androgen receptor. Mol Endocrinol 18:1120–1130CrossRefPubMed
29.
Zurück zum Zitat Krishnan V, Bullock HA, Yaden BC, Liu M, Barr RJ, Montrose-Rafizadeh C, Chen K, Dodge JA, Bryant HU (2005) The nongenotropic synthetic ligand 4-estren-3alpha17beta-diol is a high-affinity genotropic androgen receptor agonist. Mol Pharmacol 67:744–748CrossRefPubMed Krishnan V, Bullock HA, Yaden BC, Liu M, Barr RJ, Montrose-Rafizadeh C, Chen K, Dodge JA, Bryant HU (2005) The nongenotropic synthetic ligand 4-estren-3alpha17beta-diol is a high-affinity genotropic androgen receptor agonist. Mol Pharmacol 67:744–748CrossRefPubMed
30.
Zurück zum Zitat Moverare S, Venken K, Eriksson AL, Andersson N, Skrtic S, Wergedal J, Mohan S, Salmon P, Bouillon R, Gustafsson JA, Vanderschueren D, Ohlsson C (2003) Differential effects on bone of estrogen receptor alpha and androgen receptor activation in orchidectomized adult male mice. Proc Natl Acad Sci USA 100:13573–13578CrossRefPubMedPubMedCentral Moverare S, Venken K, Eriksson AL, Andersson N, Skrtic S, Wergedal J, Mohan S, Salmon P, Bouillon R, Gustafsson JA, Vanderschueren D, Ohlsson C (2003) Differential effects on bone of estrogen receptor alpha and androgen receptor activation in orchidectomized adult male mice. Proc Natl Acad Sci USA 100:13573–13578CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Seeman E (1997) From density to structure: growing up and growing old on the surfaces of bone. J Bone Miner Res 12:509–521CrossRefPubMed Seeman E (1997) From density to structure: growing up and growing old on the surfaces of bone. J Bone Miner Res 12:509–521CrossRefPubMed
32.
33.
Zurück zum Zitat Vanderschueren D, Van Herck E, Geusens P, Suiker A, Visser W, Chung K, Bouillon R (1994) Androgen resistance and deficiency have different effects on the growing skeleton of the rat. Calcif Tissue Int 55:198–203CrossRefPubMed Vanderschueren D, Van Herck E, Geusens P, Suiker A, Visser W, Chung K, Bouillon R (1994) Androgen resistance and deficiency have different effects on the growing skeleton of the rat. Calcif Tissue Int 55:198–203CrossRefPubMed
34.
Zurück zum Zitat Kawano H, Sato T, Yamada T, Matsumoto T, Sekine K, Watanabe T, Nakamura T, Fukuda T, Yoshimura K, Yoshizawa T, Aihara K, Yamamoto Y, Nakamichi Y, Metzger D, Chambon P, Nakamura K, Kawaguchi H, Kato S (2003) Suppressive function of androgen receptor in bone resorption. Proc Natl Acad Sci USA 100:9416–9421CrossRefPubMedPubMedCentral Kawano H, Sato T, Yamada T, Matsumoto T, Sekine K, Watanabe T, Nakamura T, Fukuda T, Yoshimura K, Yoshizawa T, Aihara K, Yamamoto Y, Nakamichi Y, Metzger D, Chambon P, Nakamura K, Kawaguchi H, Kato S (2003) Suppressive function of androgen receptor in bone resorption. Proc Natl Acad Sci USA 100:9416–9421CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Vandenput L, Swinnen JV, Boonen S, Van Herck E, Erben RG, Bouillon R, Vanderschueren D (2004) Role of the androgen receptor in skeletal homeostasis: the androgen-resistant testicular feminized male mouse model. J Bone Miner Res 19:1462–1470CrossRefPubMed Vandenput L, Swinnen JV, Boonen S, Van Herck E, Erben RG, Bouillon R, Vanderschueren D (2004) Role of the androgen receptor in skeletal homeostasis: the androgen-resistant testicular feminized male mouse model. J Bone Miner Res 19:1462–1470CrossRefPubMed
36.
Zurück zum Zitat Venken K, De Gendt K, Boonen S, Ophoff J, Bouillon R, Swinnen JV, Verhoeven G, Vanderschueren D (2006) Relative impact of androgen and estrogen receptor activation in the effects of androgens on trabecular and cortical bone in growing male mice: A study in the androgen receptor knock-out mouse model: A Study in the Androgen Receptor Knock-out Mouse Model. J Bone Miner Res 21:576–585CrossRefPubMed Venken K, De Gendt K, Boonen S, Ophoff J, Bouillon R, Swinnen JV, Verhoeven G, Vanderschueren D (2006) Relative impact of androgen and estrogen receptor activation in the effects of androgens on trabecular and cortical bone in growing male mice: A study in the androgen receptor knock-out mouse model: A Study in the Androgen Receptor Knock-out Mouse Model. J Bone Miner Res 21:576–585CrossRefPubMed
37.
Zurück zum Zitat Gennari L, Nuti R, Bilezikian JP (2004) Aromatase activity and bone homeostasis in men. J Clin Endocrinol Metab 89:5898–5907CrossRefPubMed Gennari L, Nuti R, Bilezikian JP (2004) Aromatase activity and bone homeostasis in men. J Clin Endocrinol Metab 89:5898–5907CrossRefPubMed
38.
Zurück zum Zitat Smith EP, Boyd J, Frank GR, Takahashi H, Cohen RM, Specker B, Williams TC, Lubahn DB, Korach KS (1994) Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 331:1056–1061CrossRefPubMed Smith EP, Boyd J, Frank GR, Takahashi H, Cohen RM, Specker B, Williams TC, Lubahn DB, Korach KS (1994) Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 331:1056–1061CrossRefPubMed
39.
Zurück zum Zitat Seeman E (2001) Clinical review 137: Sexual dimorphism in skeletal size, density, and strength. J Clin Endocrinol Metab 86:4576–4584CrossRefPubMed Seeman E (2001) Clinical review 137: Sexual dimorphism in skeletal size, density, and strength. J Clin Endocrinol Metab 86:4576–4584CrossRefPubMed
40.
Zurück zum Zitat Turner RT, Wakley GK, Hannon KS (1990) Differential effects of androgens on cortical bone histomorphometry in gonadectomized male and female rats. J Orthop Res 8:612–617CrossRefPubMed Turner RT, Wakley GK, Hannon KS (1990) Differential effects of androgens on cortical bone histomorphometry in gonadectomized male and female rats. J Orthop Res 8:612–617CrossRefPubMed
41.
Zurück zum Zitat Lea C, Kendall N, Flanagan AM (1996) Casodex (a nonsteroidal antiandrogen) reduces cancellous, endosteal, and periosteal bone formation in estrogen-replete female rats. Calcif Tissue Int 58:268–272CrossRefPubMed Lea C, Kendall N, Flanagan AM (1996) Casodex (a nonsteroidal antiandrogen) reduces cancellous, endosteal, and periosteal bone formation in estrogen-replete female rats. Calcif Tissue Int 58:268–272CrossRefPubMed
42.
Zurück zum Zitat Dagogo-Jack S, al-Ali N, Qurttom M (1997) Augmentation of bone mineral density in hirsute women. J Clin Endocrinol Metab 82:2821–2825PubMed Dagogo-Jack S, al-Ali N, Qurttom M (1997) Augmentation of bone mineral density in hirsute women. J Clin Endocrinol Metab 82:2821–2825PubMed
43.
Zurück zum Zitat Windahl SH, Vidal O, Andersson G, Gustafsson JA, Ohlsson C (1999) Increased cortical bone mineral content but unchanged trabecular bone mineral density in female ERbeta(-/-) mice. J Clin Invest 104:895–901CrossRefPubMedPubMedCentral Windahl SH, Vidal O, Andersson G, Gustafsson JA, Ohlsson C (1999) Increased cortical bone mineral content but unchanged trabecular bone mineral density in female ERbeta(-/-) mice. J Clin Invest 104:895–901CrossRefPubMedPubMedCentral
44.
Zurück zum Zitat Bouillon R, Bex M, Vanderschueren D, Boonen S (2004) Estrogens are essential for male pubertal periosteal bone expansion. J Clin Endocrinol Metab 89:6025–6029CrossRefPubMed Bouillon R, Bex M, Vanderschueren D, Boonen S (2004) Estrogens are essential for male pubertal periosteal bone expansion. J Clin Endocrinol Metab 89:6025–6029CrossRefPubMed
45.
Zurück zum Zitat Rochira V, Zirilli L, Madeo B, Aranda C, Caffagni G, Fabre B, Montangero VE, Roldan EJ, Maffei L, Carani C (2007) Skeletal effects of long-term estrogen and testosterone replacement treatment in a man with congenital aromatase deficiency: evidences of a priming effect of estrogen for sex steroids action on bone. Bone 40:1662–1668CrossRefPubMed Rochira V, Zirilli L, Madeo B, Aranda C, Caffagni G, Fabre B, Montangero VE, Roldan EJ, Maffei L, Carani C (2007) Skeletal effects of long-term estrogen and testosterone replacement treatment in a man with congenital aromatase deficiency: evidences of a priming effect of estrogen for sex steroids action on bone. Bone 40:1662–1668CrossRefPubMed
46.
Zurück zum Zitat Vidal O, Lindberg MK, Hollberg K, Baylink DJ, Andersson G, Lubahn DB, Mohan S, Gustafsson JA, Ohlsson C (2000) Estrogen receptor specificity in the regulation of skeletal growth and maturation in male mice. Proc Natl Acad Sci USA 97:5474–5479CrossRefPubMedPubMedCentral Vidal O, Lindberg MK, Hollberg K, Baylink DJ, Andersson G, Lubahn DB, Mohan S, Gustafsson JA, Ohlsson C (2000) Estrogen receptor specificity in the regulation of skeletal growth and maturation in male mice. Proc Natl Acad Sci USA 97:5474–5479CrossRefPubMedPubMedCentral
47.
Zurück zum Zitat Vanderschueren D, van Herck E, Nijs J, Ederveen AG, De Coster R, Bouillon R (1997) Aromatase inhibition impairs skeletal modeling and decreases bone mineral density in growing male rats. Endocrinology 138:2301–2307PubMed Vanderschueren D, van Herck E, Nijs J, Ederveen AG, De Coster R, Bouillon R (1997) Aromatase inhibition impairs skeletal modeling and decreases bone mineral density in growing male rats. Endocrinology 138:2301–2307PubMed
48.
Zurück zum Zitat Vanderschueren D, Venken K, Bouillon R (2004) Animal models for gender-based skeletal differences. In: Legato M (ed) Principles of gender-specific medicine. Elsevier Academic Press, pp 1043–1051 Vanderschueren D, Venken K, Bouillon R (2004) Animal models for gender-based skeletal differences. In: Legato M (ed) Principles of gender-specific medicine. Elsevier Academic Press, pp 1043–1051
49.
Zurück zum Zitat Bass S, Delmas PD, Pearce G, Hendrich E, Tabensky A, Seeman E (1999) The differing tempo of growth in bone size, mass, and density in girls is region-specific. J Clin Invest 104:795–804CrossRefPubMedPubMedCentral Bass S, Delmas PD, Pearce G, Hendrich E, Tabensky A, Seeman E (1999) The differing tempo of growth in bone size, mass, and density in girls is region-specific. J Clin Invest 104:795–804CrossRefPubMedPubMedCentral
50.
Zurück zum Zitat Jarvinen TL, Kannus P, Sievanen H (2003) Estrogen and bone–a reproductive and locomotive perspective. J Bone Miner Res 18:1921–1931CrossRefPubMed Jarvinen TL, Kannus P, Sievanen H (2003) Estrogen and bone–a reproductive and locomotive perspective. J Bone Miner Res 18:1921–1931CrossRefPubMed
51.
Zurück zum Zitat Behre HM, Kliesch S, Leifke E, Link TM, Nieschlag E (1997) Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 82:2386–2390CrossRefPubMed Behre HM, Kliesch S, Leifke E, Link TM, Nieschlag E (1997) Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 82:2386–2390CrossRefPubMed
52.
Zurück zum Zitat Manolagas SC (2000) Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 21:115–137PubMed Manolagas SC (2000) Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 21:115–137PubMed
54.
Zurück zum Zitat Hughes DE, Dai A, Tiffee JC, Li HH, Mundy GR, Boyce BF (1996) Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-b. Nat Med 2:1132–1136CrossRefPubMed Hughes DE, Dai A, Tiffee JC, Li HH, Mundy GR, Boyce BF (1996) Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-b. Nat Med 2:1132–1136CrossRefPubMed
55.
Zurück zum Zitat Michael H, Harkonen PL, Vaananen HK, Hentunen TA (2005) Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption. J Bone Miner Res 20:2224–2232CrossRefPubMed Michael H, Harkonen PL, Vaananen HK, Hentunen TA (2005) Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption. J Bone Miner Res 20:2224–2232CrossRefPubMed
56.
Zurück zum Zitat Nakamura T, Imai Y, Matsumoto T, Sato S, Takeuchi K, Igarashi K, Harada Y, Azuma Y, Krust A, Yamamoto Y, Nishina H, Takeda S, Takayanagi H, Metzger D, Kanno J, Takaoka K, Martin TJ, Chambon P, Kato S (2007) Estrogen Prevents Bone Loss via Estrogen Receptor alpha and Induction of Fas Ligand in Osteoclasts. Cell 130:811–823CrossRefPubMed Nakamura T, Imai Y, Matsumoto T, Sato S, Takeuchi K, Igarashi K, Harada Y, Azuma Y, Krust A, Yamamoto Y, Nishina H, Takeda S, Takayanagi H, Metzger D, Kanno J, Takaoka K, Martin TJ, Chambon P, Kato S (2007) Estrogen Prevents Bone Loss via Estrogen Receptor alpha and Induction of Fas Ligand in Osteoclasts. Cell 130:811–823CrossRefPubMed
57.
Zurück zum Zitat Chen Q, Kaji H, Kanatani M, Sugimoto T, Chihara K (2004) Testosterone increases osteoprotegerin mRNA expression in mouse osteoblast cells. Horm Metab Res 36:674–678CrossRefPubMed Chen Q, Kaji H, Kanatani M, Sugimoto T, Chihara K (2004) Testosterone increases osteoprotegerin mRNA expression in mouse osteoblast cells. Horm Metab Res 36:674–678CrossRefPubMed
58.
Zurück zum Zitat Bellido T, Jilka RL, Boyce BF, Girasole G, Broxmeyer H, Dalrymple SA, Murray R, Manolagas SC (1995) Regulation of interleukin-6, osteoclastogenesis, and bone mass by androgens. The role of the androgen receptor. J Clin Invest 95:2886–2895CrossRefPubMedPubMedCentral Bellido T, Jilka RL, Boyce BF, Girasole G, Broxmeyer H, Dalrymple SA, Murray R, Manolagas SC (1995) Regulation of interleukin-6, osteoclastogenesis, and bone mass by androgens. The role of the androgen receptor. J Clin Invest 95:2886–2895CrossRefPubMedPubMedCentral
59.
Zurück zum Zitat Huber DM, Bendixen AC, Pathrose P, Srivastava S, Dienger KM, Shevde NK, Pike JW (2001) Androgens suppress osteoclast formation induced by RANKL and macrophage-colony stimulating factor. Endocrinology 142:3800–3808CrossRefPubMed Huber DM, Bendixen AC, Pathrose P, Srivastava S, Dienger KM, Shevde NK, Pike JW (2001) Androgens suppress osteoclast formation induced by RANKL and macrophage-colony stimulating factor. Endocrinology 142:3800–3808CrossRefPubMed
60.
Zurück zum Zitat Riggs BL, Khosla S, Melton LJ 3rd (2002) Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 23:279–302CrossRefPubMed Riggs BL, Khosla S, Melton LJ 3rd (2002) Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 23:279–302CrossRefPubMed
61.
62.
Zurück zum Zitat Seeman E (2003) Periosteal bone formation–a neglected determinant of bone strength. N Engl J Med 349:320–323CrossRefPubMed Seeman E (2003) Periosteal bone formation–a neglected determinant of bone strength. N Engl J Med 349:320–323CrossRefPubMed
63.
Zurück zum Zitat Vandenput L, Boonen S, Van Herck E, Swinnen JV, Bouillon R, Vanderschueren D (2002) Evidence from the aged orchidectomized male rat model that 17beta-estradiol is a more effective bone-sparing and anabolic agent than 5alpha-dihydrotestosterone. J Bone Miner Res 17:2080–2086CrossRefPubMed Vandenput L, Boonen S, Van Herck E, Swinnen JV, Bouillon R, Vanderschueren D (2002) Evidence from the aged orchidectomized male rat model that 17beta-estradiol is a more effective bone-sparing and anabolic agent than 5alpha-dihydrotestosterone. J Bone Miner Res 17:2080–2086CrossRefPubMed
64.
Zurück zum Zitat Venken K, Boonen S, Van Herck E, Vandenput L, Kumar N, Sitruk-Ware R, Sundaram K, Bouillon R, Vanderschueren D (2005) Bone and muscle protective potential of the prostate-sparing synthetic androgen 7alpha-methyl-19-nortestosterone: Evidence from the aged orchidectomized male rat model. Bone 36:663–670CrossRefPubMed Venken K, Boonen S, Van Herck E, Vandenput L, Kumar N, Sitruk-Ware R, Sundaram K, Bouillon R, Vanderschueren D (2005) Bone and muscle protective potential of the prostate-sparing synthetic androgen 7alpha-methyl-19-nortestosterone: Evidence from the aged orchidectomized male rat model. Bone 36:663–670CrossRefPubMed
65.
Zurück zum Zitat Riggs BL, Parfitt AM (2005) Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling. J Bone Miner Res 20:177–184CrossRefPubMed Riggs BL, Parfitt AM (2005) Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling. J Bone Miner Res 20:177–184CrossRefPubMed
66.
Zurück zum Zitat Barrett-Connor E, Mueller JE, van Mühlen DG, Laughlin GA, Schneider DL, Sartoris DJ (2000) Low levels of estradiol are associated with vertebral fractures in older men but not in women. The Rancho Bernardo Study. J Clin Endocrinol Metab 85:219–223PubMed Barrett-Connor E, Mueller JE, van Mühlen DG, Laughlin GA, Schneider DL, Sartoris DJ (2000) Low levels of estradiol are associated with vertebral fractures in older men but not in women. The Rancho Bernardo Study. J Clin Endocrinol Metab 85:219–223PubMed
67.
Zurück zum Zitat Van Pottelbergh I, Goemaere S, Kaufman JM (2003) Bioavailable estradiol and an aromatase gene polymorphism are determinants of bone mineral density changes in men over 70 years of age. J Clin Endocrinol Metab 88:3075–3081CrossRefPubMed Van Pottelbergh I, Goemaere S, Kaufman JM (2003) Bioavailable estradiol and an aromatase gene polymorphism are determinants of bone mineral density changes in men over 70 years of age. J Clin Endocrinol Metab 88:3075–3081CrossRefPubMed
68.
Zurück zum Zitat Riggs BL, Khosla S, Melton LJ 3rd (1998) A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res 13:763–773CrossRefPubMed Riggs BL, Khosla S, Melton LJ 3rd (1998) A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res 13:763–773CrossRefPubMed
69.
70.
Zurück zum Zitat Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Holmes JH, Dlewati A, Staley J, Santanna J, Kapoor SC, Attie MF, Haddad Jr JG, Strom BL (1999) Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 84:1966–1972PubMed Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Holmes JH, Dlewati A, Staley J, Santanna J, Kapoor SC, Attie MF, Haddad Jr JG, Strom BL (1999) Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 84:1966–1972PubMed
71.
Zurück zum Zitat Kenny AM, Prestwood KM, Marcello KM, Raisz LG (2000) Determinants of bone density in healthy older men with low testosterone levels. J Gerontol A Biol Sci Med Sci 55A:M492–M497CrossRef Kenny AM, Prestwood KM, Marcello KM, Raisz LG (2000) Determinants of bone density in healthy older men with low testosterone levels. J Gerontol A Biol Sci Med Sci 55A:M492–M497CrossRef
72.
Zurück zum Zitat Emmelot-Vonk MH, Verhaar HJ, Nakhai Pour HR, Aleman A, Lock TM, Bosch JL, Grobbee DE, van der Schouw YT (2008) Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. Jama 299:39–52PubMed Emmelot-Vonk MH, Verhaar HJ, Nakhai Pour HR, Aleman A, Lock TM, Bosch JL, Grobbee DE, van der Schouw YT (2008) Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. Jama 299:39–52PubMed
73.
Zurück zum Zitat Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. Jama 288:321–333CrossRefPubMed Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. Jama 288:321–333CrossRefPubMed
74.
Zurück zum Zitat Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O’Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, Van Horn L, Wactawski-Wende J, Wallace R, Wassertheil-Smoller S (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. Jama 291:1701–1712CrossRefPubMed Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O’Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, Van Horn L, Wactawski-Wende J, Wallace R, Wassertheil-Smoller S (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. Jama 291:1701–1712CrossRefPubMed
75.
Zurück zum Zitat Johnell O, Kanis JA, Black DM, Balogh A, Poor G, Sarkar S, Zhou C, Pavo I (2004) Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study. J Bone Miner Res 19:764–772CrossRefPubMed Johnell O, Kanis JA, Black DM, Balogh A, Poor G, Sarkar S, Zhou C, Pavo I (2004) Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study. J Bone Miner Res 19:764–772CrossRefPubMed
76.
Zurück zum Zitat Seeman E, Crans GG, Diez-Perez A, Pinette KV, Delmas PD (2006) Anti-vertebral fracture efficacy of raloxifene: a meta-analysis. Osteoporos Int 17:313–316CrossRefPubMed Seeman E, Crans GG, Diez-Perez A, Pinette KV, Delmas PD (2006) Anti-vertebral fracture efficacy of raloxifene: a meta-analysis. Osteoporos Int 17:313–316CrossRefPubMed
77.
Zurück zum Zitat McDonnell DP, Clemm DL, Hermann T, Goldman ME, Pike JW (1995) Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol Endocrinol 9:659–669PubMed McDonnell DP, Clemm DL, Hermann T, Goldman ME, Pike JW (1995) Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol Endocrinol 9:659–669PubMed
79.
Zurück zum Zitat Bhasin S, Calof OM, Storer TW, Lee ML, Mazer NA, Jasuja R, Montori VM, Gao W, Dalton JT (2006) Drug insight: Testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. Nat Clin Pract Endocrinol Metab 2:146–159CrossRefPubMedPubMedCentral Bhasin S, Calof OM, Storer TW, Lee ML, Mazer NA, Jasuja R, Montori VM, Gao W, Dalton JT (2006) Drug insight: Testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. Nat Clin Pract Endocrinol Metab 2:146–159CrossRefPubMedPubMedCentral
Metadaten
Titel
Sex hormones, their receptors and bone health
verfasst von
K. Venken
F. Callewaert
S. Boonen
D. Vanderschueren
Publikationsdatum
01.11.2008
Verlag
Springer London
Erschienen in
Osteoporosis International / Ausgabe 11/2008
Print ISSN: 0937-941X
Elektronische ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-008-0609-z

Weitere Artikel der Ausgabe 11/2008

Osteoporosis International 11/2008 Zur Ausgabe

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Knie-TEP: Kein Vorteil durch antibiotikahaltigen Knochenzement

29.05.2024 Periprothetische Infektionen Nachrichten

Zur Zementierung einer Knie-TEP wird in Deutschland zu über 98% Knochenzement verwendet, der mit einem Antibiotikum beladen ist. Ob er wirklich besser ist als Zement ohne Antibiotikum, kann laut Registerdaten bezweifelt werden.

Häusliche Gewalt in der orthopädischen Notaufnahme oft nicht erkannt

28.05.2024 Häusliche Gewalt Nachrichten

In der Notaufnahme wird die Chance, Opfer von häuslicher Gewalt zu identifizieren, von Orthopäden und Orthopädinnen offenbar zu wenig genutzt. Darauf deuten die Ergebnisse einer Fragebogenstudie an der Sahlgrenska-Universität in Schweden hin.

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Fehlerkultur Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Mehr Frauen im OP – weniger postoperative Komplikationen

21.05.2024 Allgemeine Chirurgie Nachrichten

Ein Frauenanteil von mindestens einem Drittel im ärztlichen Op.-Team war in einer großen retrospektiven Studie aus Kanada mit einer signifikanten Reduktion der postoperativen Morbidität assoziiert.

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.